001437022 000__ 05418cam\a2200565\a\4500
001437022 001__ 1437022
001437022 003__ OCoLC
001437022 005__ 20230309004126.0
001437022 006__ m\\\\\o\\d\\\\\\\\
001437022 007__ cr\un\nnnunnun
001437022 008__ 210602s2021\\\\sz\\\\\\o\\\\\000\0\eng\d
001437022 019__ $$a1255228882$$a1262672699$$a1264749330
001437022 020__ $$a9783030707736$$q(electronic bk.)
001437022 020__ $$a3030707733$$q(electronic bk.)
001437022 020__ $$a9783030707743$$q(print)
001437022 020__ $$a3030707741
001437022 020__ $$a9783030707750$$q(print)
001437022 020__ $$a303070775X
001437022 020__ $$z3030707725
001437022 020__ $$z9783030707729
001437022 0247_ $$a10.1007/978-3-030-70773-6$$2doi
001437022 035__ $$aSP(OCoLC)1253476222
001437022 040__ $$aYDX$$beng$$epn$$cYDX$$dGW5XE$$dEBLCP$$dOCLCO$$dVT2$$dDKU$$dUKAHL$$dOCLCQ$$dOCLCO$$dCOM$$dSFB$$dCASUM$$dOCLCQ
001437022 049__ $$aISEA
001437022 050_4 $$aRC280.L5
001437022 08204 $$a616.99/4360642$$223
001437022 24500 $$aLiver intra-arterial PRRT with 111In-Octreotide :$$bthe tumoricidal efficacy of 111In auger electron emission /$$cGeorgios S. Limouris, editor.
001437022 260__ $$aCham :$$bSpringer,$$c2021.
001437022 300__ $$a1 online resource
001437022 336__ $$atext$$btxt$$2rdacontent
001437022 337__ $$acomputer$$bc$$2rdamedia
001437022 338__ $$aonline resource$$bcr$$2rdacarrier
001437022 347__ $$atext file
001437022 347__ $$bPDF
001437022 5050_ $$aThe efficacy of auger and internal conversion electron emission 0f in-111 to treat neuroendocrine tumors -- Somatostatin -- Gastro-entero-pancreatic neuroendocrine tumors -- [111in-dtpa0-d-phe1] -- octreotide: the ligand -the receptor-label -- Regulations and requirements of hospitals performing radio-infusions -- Intravenous radio-peptide infusion with in-octreotide -- Intra-arterial radio-peptide infusion -- Radio-peptide infusions after implementation of an intra-arterial port system -- US, CT and MRI for the evaluation of patients with neuroendocrine tumors -- Angiographic anatomy on the course of liver intra-arterial infusion -- Liver radio-infusions: identifying anatomic variants -- Dosimetry and dose calculation: its necessity in radio-peptide therapy -- Evaluation and assessment of the radio-peptide treatment efficacy -- Intra-venous radio-peptide infusions with in-octreotide for the treatment of bronchial carcinoids -- Intra-arterial radio -- peptide infusions for the treatment of colorectal carcinomas -- Intra-arterial radio-peptide infusions for the treatment of paragangliomas -- Intra-arterial radio-peptide infusions for the treatment of brain meningiomas -- Surgery in neuroendocrine tumors -- Cytoreductive surgery combined with intraperitoneal [111in-dtpa0 d-phe1]-octreotide infusions in neuroendocrine character metastases -- Patients survival followed intra-arterial versus intravenous infusions -- Complications and side effects on the course of liver-radio-infusions -- Progression free survival and response rate in neuroendocrine liver metastasized patients, treated with in-111 octreotide -- Therapy response vs variability of tumor size, absorbed dose, and ki-67 index after in-111 octreotide intra-arterial infusions.
001437022 506__ $$aAccess limited to authorized users.
001437022 520__ $$aThis book describes in detail a clinical project that reveals the tumoricidal efficacy of Auger and internal conversion electrons, emitted from n.c.a. 111In and implemented in oncology as a treating armamentarium for peptide receptor radionuclide therapy (PRRT), targeting small size (² d"20 mm) tumors and micro-metastases. The keen interest in n.c.a. 111In began when it was observed that its Auger electron emission could be highly radiotoxic, due to its high LET when it decayed in the vicinity of cellular DNA. The somatostatin analog octreotide, labeled with [111In-diethylenetriaminepentaacetic acid (DTPA0-D-Phe1)] is an established diagnostic agent for the imaging of somatostatin receptor-positive neuro- (or non-neuro) endocrine tumors. It relies on receptor-mediated binding, internalization and installation in the lysosomes in the proximity of the nucleus; administered in large doses, loco-regionally, via the feeding artery of solid tumors, can be highly radiotoxic if they over-express somatostatin receptors, mainly of the sst2 histotype. The book compares the results between i.v. and i.a. implementation in more than 80 patients after over 800 i.a. infusions in neuroendocrine tumors, meningiomas, paragangliomas and colorectal carcinomas in a single Institute (Aretaieion University Hospital) and encourages the i.a. way, leading to tumor melting while minimizing the toxicity to healthy peritumoral liver tissue and critical organs (kidneys and bone marrow). The volume is an invaluable tool for nuclear medicine physicians, interventional radiologists and oncologists dealing with radiopeptide therapies
001437022 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed June 10, 2021).
001437022 650_0 $$aLiver$$xCancer$$xRadiotherapy.
001437022 650_6 $$aFoie$$xCancer$$xRadiothérapie.
001437022 655_7 $$aLlibres electrònics.$$2thub
001437022 655_0 $$aElectronic books.
001437022 7001_ $$aLimouris, Georgios S.,$$eeditor.
001437022 77608 $$iPrint version:$$tLiver intra-arterial PRRT with 111In-Octreotide.$$dCham : Springer, 2021$$z3030707725$$z9783030707729$$w(OCoLC)1237353674
001437022 852__ $$bebk
001437022 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-70773-6$$zOnline Access$$91397441.1
001437022 909CO $$ooai:library.usi.edu:1437022$$pGLOBAL_SET
001437022 980__ $$aBIB
001437022 980__ $$aEBOOK
001437022 982__ $$aEbook
001437022 983__ $$aOnline
001437022 994__ $$a92$$bISE